326 related articles for article (PubMed ID: 36720271)
1. Real-world effectiveness of a single dose of mpox vaccine in males.
Wolff Sagy Y; Zucker R; Hammerman A; Markovits H; Arieh NG; Abu Ahmad W; Battat E; Ramot N; Carmeli G; Mark-Amir A; Wagner-Kolasko G; Duskin-Bitan H; Yaron S; Peretz A; Arbel R; Lavie G; Netzer D
Nat Med; 2023 Mar; 29(3):748-752. PubMed ID: 36720271
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study.
Bertran M; Andrews N; Davison C; Dugbazah B; Boateng J; Lunt R; Hardstaff J; Green M; Blomquist P; Turner C; Mohammed H; Cordery R; Mandal S; Campbell C; Ladhani SN; Ramsay M; Amirthalingam G; Bernal JL
Lancet Infect Dis; 2023 Jul; 23(7):828-835. PubMed ID: 36924787
[TBL] [Abstract][Full Text] [Related]
3. Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response.
Ladhani SN; Dowell AC; Jones S; Hicks B; Rowe C; Begum J; Wailblinger D; Wright J; Owens S; Pickering A; Shilltoe B; McMaster P; Whittaker E; Zuo J; Powell A; Amirthalingam G; Mandal S; Lopez-Bernal J; Ramsay ME; Kissane N; Bell M; Watson H; Ho D; Hallis B; Otter A; Moss P; Cohen J
Lancet Infect Dis; 2023 Sep; 23(9):1042-1050. PubMed ID: 37336224
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study.
Fontán-Vela M; Hernando V; Olmedo C; Coma E; Martínez M; Moreno-Perez D; Lorusso N; Vázquez Torres M; Barbas Del Buey JF; Roig-Sena J; Pastor E; Galmés Truyols A; Artigues Serra F; Sancho Martínez RM; Latasa Zamalloa P; Pérez Martínez O; Vázquez Estepa A; García Rojas AJ; Barreno Estévez AI; Sánchez-Migallón Naranjo A; Pérez Martín JJ; Peces Jiménez P; Morales Romero R; Castilla J; García Cenoz M; Huerta Huerta M; Boone ALD; Macías Ortiz MJ; Álvarez Río V; Rodríguez Recio MJ; Merino Díaz M; Berradre Sáenz B; Villegas-Moreno MT; Limia A; Diaz A; Monge S;
Clin Infect Dis; 2024 Feb; 78(2):476-483. PubMed ID: 37864849
[TBL] [Abstract][Full Text] [Related]
5. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons - 43 U.S. Jurisdictions, July 31-October 1, 2022.
Payne AB; Ray LC; Cole MM; Canning M; Houck K; Shah HJ; Farrar JL; Lewis NM; Fothergill A; White EB; Feldstein LR; Roper LE; Lee F; Kriss JL; Sims E; Spicknall IH; Nakazawa Y; Gundlapalli AV; Shimabukuro T; Cohen AL; Honein MA; Mermin J; Payne DC
MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(49):1560-1564. PubMed ID: 36480479
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection - New York, 2022.
Rosenberg ES; Dorabawila V; Hart-Malloy R; Anderson BJ; Miranda W; O'Donnell T; Gonzalez CJ; Abrego M; DelBarba C; Tice CJ; McGarry C; Mitchell EC; Boulais M; Backenson B; Kharfen M; McDonald J; Bauer UE
MMWR Morb Mortal Wkly Rep; 2023 May; 72(20):559-563. PubMed ID: 37339074
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022.
Merad Y; Gaymard A; Cotte L; Perpoint T; Alfaiate D; Godinot M; Becker A; Cannesson O; Batalla AS; Oria-Yassir F; Landré S; Morfin F; Bouscambert M; Valour F; Ader F; Conrad A
Euro Surveill; 2022 Dec; 27(50):. PubMed ID: 36695469
[TBL] [Abstract][Full Text] [Related]
8. Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons - 29 U.S. Jurisdictions, May 22-September 3, 2022.
Farrar JL; Lewis NM; Houck K; Canning M; Fothergill A; Payne AB; Cohen AL; Vance J; Brassil B; Youngkin E; Glenn B; Mangla A; Kupferman N; Saunders K; Meza C; Nims D; Soliva S; Blouse B; Henderson T; Banerjee E; White B; Birn R; Stadelman AM; Abrego M; McLafferty M; Eberhart MG; Pietrowski M; De León SM; Creegan E; Diedhiou A; Wiedeman C; Murray-Thompson J; McCarty E; Marcinkevage J; Kocharian A; Torrone EA; Ray LC; Payne DC;
MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(5152):1610-1615. PubMed ID: 36580416
[TBL] [Abstract][Full Text] [Related]
9. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals.
Zaeck LM; Lamers MM; Verstrepen BE; Bestebroer TM; van Royen ME; Götz H; Shamier MC; van Leeuwen LPM; Schmitz KS; Alblas K; van Efferen S; Bogers S; Scherbeijn S; Rimmelzwaan GF; van Gorp ECM; Koopmans MPG; Haagmans BL; GeurtsvanKessel CH; de Vries RD
Nat Med; 2023 Jan; 29(1):270-278. PubMed ID: 36257333
[TBL] [Abstract][Full Text] [Related]
10. Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study.
Muller MP; Navarro C; Wilson SE; Shulha HP; Naus M; Lim G; Padhi S; McGeer A; Finkelstein M; Liddy A; Bettinger JA;
Vaccine; 2024 Jan; 42(3):535-540. PubMed ID: 38199921
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study.
Mazzotta V; Lepri AC; Matusali G; Cimini E; Piselli P; Aguglia C; Lanini S; Colavita F; Notari S; Oliva A; Meschi S; Casetti R; Mondillo V; Vergori A; Bettini A; Grassi G; Pinnetti C; Lapa D; Tartaglia E; Gallì P; Mondi A; Montagnari G; Gagliardini R; Nicastri E; Lichtner M; Sarmati L; Tamburrini E; Mastroianni C; Stingone C; Siddu A; Barca A; Fontana C; Agrati C; Girardi E; Vaia F; Maggi F; Antinori A;
EClinicalMedicine; 2024 Feb; 68():102420. PubMed ID: 38292040
[TBL] [Abstract][Full Text] [Related]
12. Characterizing the acute antibody response of monkeypox and MVA-BN vaccine following an Australian outbreak.
Asquith W; Hueston L; Dwyer D; Kok J; Ko D; Fennel M; Rockett R; Rai NJ; Li Y; Sriramoju S; Sutor A; O'Sullivan M
J Med Virol; 2024 Jan; 96(1):e29407. PubMed ID: 38240403
[TBL] [Abstract][Full Text] [Related]
13. Current Status of Vaccine Development for Monkeypox Virus.
Rastogi A; Kumar M
Adv Exp Med Biol; 2024; 1451():289-300. PubMed ID: 38801585
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Monkeypox Among Unvaccinated Persons Compared with Persons Receiving ≥1 JYNNEOS Vaccine Dose - 32 U.S. Jurisdictions, July 31-September 3, 2022.
Payne AB; Ray LC; Kugeler KJ; Fothergill A; White EB; Canning M; Farrar JL; Feldstein LR; Gundlapalli AV; Houck K; Kriss JL; Lewis NM; Sims E; Smith DK; Spicknall IH; Nakazawa Y; Damon IK; Cohn AC; Payne DC
MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(40):1278-1282. PubMed ID: 36201401
[TBL] [Abstract][Full Text] [Related]
15. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study - United States, August 19, 2022-March 31, 2023.
Dalton AF; Diallo AO; Chard AN; Moulia DL; Deputy NP; Fothergill A; Kracalik I; Wegner CW; Markus TM; Pathela P; Still WL; Hawkins S; Mangla AT; Ravi N; Licherdell E; Britton A; Lynfield R; Sutton M; Hansen AP; Betancourt GS; Rowlands JV; Chai SJ; Fisher R; Danza P; Farley M; Zipprich J; Prahl G; Wendel KA; Niccolai L; Castilho JL; Payne DC; Cohn AC; Feldstein LR; ;
MMWR Morb Mortal Wkly Rep; 2023 May; 72(20):553-558. PubMed ID: 37200229
[TBL] [Abstract][Full Text] [Related]
16. Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox.
Deng L; Lopez LK; Glover C; Cashman P; Reynolds R; Macartney K; Wood N
JAMA; 2023 Jun; 329(23):2091-2094. PubMed ID: 37145654
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of the Modified Vaccinia Ankara Vaccine Against Mpox in Men Who Have Sex With Men: A Retrospective Cohort Analysis, Seattle, Washington.
Ramchandani MS; Berzkalns A; Cannon CA; Dombrowski JC; Brown E; Chow EJ; Barash E; Pogosjans S; Smith D; Golden MR
Open Forum Infect Dis; 2023 Nov; 10(11):ofad528. PubMed ID: 37942460
[TBL] [Abstract][Full Text] [Related]
18. Progress and prospects on vaccine development against monkeypox infection.
Saadh MJ; Ghadimkhani T; Soltani N; Abbassioun A; Daniel Cosme Pecho R; Taha A; Jwad Kazem T; Yasamineh S; Gholizadeh O
Microb Pathog; 2023 Jul; 180():106156. PubMed ID: 37201635
[TBL] [Abstract][Full Text] [Related]
19. Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals.
Hubert M; Guivel-Benhassine F; Bruel T; Porrot F; Planas D; Vanhomwegen J; Wiedemann A; Burrel S; Marot S; Palich R; Monsel G; Diombera H; Gallien S; Lopez-Zaragoza JL; Vindrios W; Taieb F; Fernandes-Pellerin S; Delhaye M; Laude H; Arowas L; Ungeheuer MN; Hocqueloux L; Pourcher V; Prazuck T; Marcelin AG; Lelièvre JD; Batéjat C; Lévy Y; Manuguerra JC; Schwartz O
Cell Host Microbe; 2023 Jun; 31(6):937-948.e4. PubMed ID: 37196656
[TBL] [Abstract][Full Text] [Related]
20. Case study: breakthrough mpox infection in Aotearoa New Zealand and Australia after completed two-dose course of subcutaneous modified vaccinia Ankara (MVA-BN) vaccines.
Cornelisse VJ; Kearley JJM; Vargas Castillo J; Macharg L; McLaughlin VA; Jack SJ; Swift C
Sex Health; 2023 Dec; 20(6):585-587. PubMed ID: 37852607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
